{
  "docId": "019de076-b8a1-76db-a88b-3941d3b29d31",
  "docSlug": "785649d6ad3bf1f87bd264132bed44c1",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 25,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide presents experimental evidence (Western blot) supporting the mechanism of action for NXP800 in ARID1a-deficient cancer cells.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/8",
  "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31",
  "deckJsonHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31.json",
  "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Western blot image showing ATF4, ATF3, CHAC1, and Cleaved PARP expression across Wildtype, Heterozygote, and Homozygote cells at 0, 2, 6, 24 hours.",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27a245ea-7b55-44cc-8383-de508ff3d675",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.38,
        "x": 0.58,
        "y": 0.2
      },
      "kind": "list",
      "text": "Activation of the ATF4/ATF3/ CHAC1 cascade in the ARID1A wildtype, heterozygote and homozygote HCT116 human colorectal cancer cells. Expression of cleaved PARP, an apoptotic marker, is markedly induced only in heterozygote and homozygote ARID1a mutant HCT116 cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e484dfc8-5a32-4c14-b579-7fe652c65f46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Isogenic HCT116 Cell Model",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13f5fcdc-bcaf-4a86-93e5-40d924cce953",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Paul Workman, Molecular targets and Cancer Therapeutics, oral presentation, 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "523f2783-2ecb-4c56-8353-a9e435201fd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Loss of ARID1a Sensitizes Cells to NXP800-induced Apoptosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df999468-6dde-4ecc-889a-fb79f75b05ab",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "5ec35aed-a9e8-466d-b33e-49c6abeaaeef",
      "evidence": "list/bullet: Activation of the ATF4/ATF3/ CHAC1 cascade in the ARID1A wildtype, heterozygote and homozygote HCT116 human colorectal cancer cells.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 7,
      "beatId": "816636d5-21da-498e-b716-dab6ea2ab36b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Mechanism of Action and clinical results for NXP800",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431",
      "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts",
      "position": 0,
      "objective": "Highlight the need for new cancer treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}